Article
Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.
Science advances - 25 Sept 2026
Geraud Mathéa, Gence Remi, Casanova Anne, Taranchon-Clermont Estelle, Salimbeni Simona, Özsu Nesibe, Vienne Maina, Delahaye Célia, Borrull Elodie, Lusque Amélie, Morisseau Mathilde, Filleron Thomas, Pagan Delphine, Taha Camille, Cristini Agnese, Mazières Julien, Calvayrac Olivier, Favre Gilles, Pradines Anne, Sordet Olivier
Abstract excerpt
Resistance to targeted cancer therapies often arises from drug-tolerant cells, which survive treatment by entering a nonproliferative state. Over time, these cells can acquire mutations that contribute to cell reproliferation, but how nonproliferating drug-tolerant cells accumulate these mutations remains unclear. Here, we show that EGFR inhibition in EGFR-mutated lung cancer transiently down-regulates...
Read the complete abstract on PubMedTopics
- DNA Topoisomerases, Type I
- Drug Resistance, Neoplasm
- ErbB Receptors
- Lung Neoplasms